Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Assets (2016 - 2026)

Heron Therapeutics filings provide 16 years of Non-Current Assets readings, the most recent being $17.2 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 24.79% to $17.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $75.8 million, a 23.94% decrease, with the full-year FY2025 number at $17.8 million, down 26.2% from a year prior.
  • Non-Current Assets hit $17.2 million in Q1 2026 for Heron Therapeutics, down from $17.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $51.1 million in Q1 2022 to a low of $17.2 million in Q1 2026.
  • Median Non-Current Assets over the past 5 years was $32.0 million (2024), compared with a mean of $32.3 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 32.95% in 2022 and later fell 28.46% in 2024.
  • Heron Therapeutics' Non-Current Assets stood at $45.5 million in 2022, then dropped by 25.89% to $33.7 million in 2023, then fell by 28.46% to $24.1 million in 2024, then dropped by 26.2% to $17.8 million in 2025, then fell by 3.25% to $17.2 million in 2026.
  • The last three reported values for Non-Current Assets were $17.2 million (Q1 2026), $17.8 million (Q4 2025), and $19.6 million (Q3 2025) per Business Quant data.